---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121827"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:52:25.438256+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma Q3 net loss $16.6M; Phase 3 TANDEM topline expected Q4 2024

## Summary
- Cash $422.7M as of Sep 30, 2024, up from $340.5M at Dec 31, 2023.
- Revenue $29.1M in Q3 2024 from Menarini milestone; net loss $16.6M vs $47.1M in Q3 2023.
- Phase 3 TANDEM topline data now expected in Q4 2024 due to faster enrollment.
- On track for BROADWAY topline data in Q4 2024; BROOKLYN data at AHA Nov 16-18.

## SEC filing metadata
- accession: 0000950170-24-121827
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017024121827/0000950170-24-121827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017024121827/nams-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121827
- JSON: https://secwatch.observer/filing/0000950170-24-121827.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121827.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.